New Approaches To AF Ablation And Mapping

The market for atrial fibrillation catheter ablation devices continues to grow even as the field wrestles with basic questions and as new study results may dampen enthusiasm for some technologies. Though strategics dominate this sector, innovators with new approaches to ablation and mapping hope to help resolve unknowns and take a piece of this vast and underpenetrated market.

Atrial fibrillation (AF or Afib), a condition in which the heart’s atria receive disorganized, irregular electrical signals that cause them to essentially twitch rather than beat, is on the rise worldwide. Catheter ablation of the heart and/or pulmonary veins is a useful treatment for some types of atrial fibrillation, but the procedure carries significant relapse rates, particularly in patients with more severe Afib. The catheter-based Afib ablation landscape is dominated by strategics including St. Jude Medical Inc., Biosense Webster Inc.(a Johnson & Johnsoncompany), Medtronic PLC, Boston Scientific Corp. and Abbott Laboratories Inc., which have made important moves recently. (Also see "Device Companies Follow New Map To Atrial Fibrillation" - Medtech Insight, 7 December, 2012.) But not everyone agrees on whether better mapping technologies or better catheters are the future of Afib ablation, and recent trial results have unsettled many insiders. Smaller companies, in the meantime, are innovating in both. (See Figure 1.) Moreover, one company is working on a completely noninvasive approach. (See sidebar below: CyberHeart Takes Noninvasive Approach To AF Ablation.)

Between 2.7 and 6.1 million people in the US and 33 million worldwide suffer from Afib, and the numbers are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

Fallouh Healthcare Receives Grant Funding From Innovate UK

 

Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.

Volta Files For US FDA Approval Of Next-Gen Cardio Mapping Software After Winning Labeling Expansion

 
• By 

Volta Medical received a labeling expansion for its AF-Xplorer mapping software to treat A-fib, which provides the clinical evidence needed to broaden US access. The company hopes for FDA clearance for its improved second-gen AF-Xplorer II software.

Medtronic Announces Collaboration To Create A ‘New Era’ in Surgical Training

 

Medtronic is teaming up with IRCAD North America to build high-tech training and education experiences for surgeons and medical professionals in cardiovascular, neuroscience, and minimally invasive surgical specialties. The move could also further position Medtronic to seize on the growing robotics

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.

More from Device Area

UK MHRA Joins New Global Network For Safe Use Of AI In Healthcare

 

The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.

Volta Files For US FDA Approval Of Next-Gen Cardio Mapping Software After Winning Labeling Expansion

 
• By 

Volta Medical received a labeling expansion for its AF-Xplorer mapping software to treat A-fib, which provides the clinical evidence needed to broaden US access. The company hopes for FDA clearance for its improved second-gen AF-Xplorer II software.

Home-Testing Added To UK National Cervical Cancer Screening Program

 

NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.